ABBV AbbVie Inc
FY2025 10-K
AbbVie Inc (ABBV) filed its fiscal year 2025 10-K annual report with the SEC on Feb 20, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: global biopharmaceutical company focused on innovative therapies in immunology, neuroscience, oncology, aesthetics, and eye care
- • New emphasis: expanded indications and geographic approvals for Skyrizi and Rinvoq across autoimmune diseases, plus new oncology ADC Epkinly approved for lymphoma
Management Discussion & Analysis
- • Revenue $61.2B, up 9% YoY on reported and constant currency basis
- • Operating earnings $15.1B, operating margin approximately 24.7% (15.1B/61.2B)
Risk Factors
- • FDA approval and EC marketing authorization for Rinvoq in 2025 for giant cell arteritis and ulcerative colitis, supporting U.S. exclusivity through April 2037
- • Global minimum tax "Pillar Two" implementation starting 2024 raising future income tax expense uncertainty under OECD rules
Financial SummaryXBRL
Revenue
$61.2B
Net Income
$4.2B
Gross Margin
19.7%
Operating Margin
24.6%
Net Margin
6.9%
ROE
-129.2%
Total Assets
$134.0B
EPS (Diluted)
$2.36
Operating Cash Flow
$19.0B
Source: XBRL data from AbbVie Inc FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on AbbVie Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.